Today: 9 June 2026
Guidewire Software stock slides 6.7% into weekend; what GWRE investors watch next
4 January 2026
1 min read

Guidewire Software stock slides 6.7% into weekend; what GWRE investors watch next

NEW YORK, Jan 4, 2026, 11:12 ET — Market closed

  • GWRE slid sharply on the first trading day of 2026, leaving the stock on watch for a technical reset into Monday.
  • Investors are still digesting Guidewire’s raised fiscal-year outlook from December, with ARR and cloud momentum in focus.
  • The next catalysts include U.S. jobs and inflation data this week and Guidewire’s next earnings window in early March.

Guidewire Software, Inc. shares closed down 6.7% on Friday at $187.63 and last traded around $189 in after-hours activity.

That drop pushed GWRE well below its 50-day and 200-day moving averages — roughly $215 and $220 — levels derived from past prices that many traders use as trend markers. Its 14-day relative strength index, a momentum gauge, sat near 30, a reading often associated with “oversold” conditions.

The move came as U.S. stocks ended mixed and Treasury yields climbed in a session marked by uneven participation after the New Year’s holiday. “Today is kind of a holiday trading day, lighter volumes,” said Jed Ellerbroek, a portfolio manager at Argent Capital in St. Louis. Reuters

Guidewire traded between $187.54 and $200.92 on Friday, with about 806,660 shares changing hands. The company’s market capitalization is about $16 billion and the stock is in a 52-week range of roughly $165 to $273, according to Public.com data.

Company-specific news was limited in the past two days, leaving investors anchored to the last formal update on Dec. 3, when Guidewire reported first-quarter revenue of $332.6 million, up 27%, and annual recurring revenue (ARR) — a measure of subscription value under contract — of $1.063 billion. It forecast second-quarter revenue of $339 million to $345 million and guided to fiscal 2026 ending ARR of $1.220 billion to $1.230 billion.

Guidewire sells core systems software used by property-and-casualty insurers to run policy administration, billing and claims, and it has been pushing customers toward cloud subscriptions. That shift can make quarter-to-quarter results sensitive to the timing of large customer decisions and implementation schedules.

Sell-side analysts remain broadly constructive despite the recent pullback. StockAnalysis.com shows a “Buy” consensus and an average price target of $271.69, though targets span from $160 to $305.

Guidewire competes with a mix of vertical insurance-technology vendors and in-house development at large insurers, with deal cycles often tied to multi-year modernization programs. For traders, the stock’s break below long-term averages means it can start to trade more like a sentiment barometer than a fundamentals story in the short run.

But the downside scenario is straightforward: if cloud migrations slow, or if insurers take longer to sign and expand contracts, ARR growth and margin leverage can disappoint in a stock that still screens expensive on traditional earnings measures. Rising long-end yields can also keep pressure on software valuations.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals
Previous Story

RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop